Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

September 2016 | 142 pages | ID: C957821060CEN
MarketsandMarkets

Abstracts

The global cancer immunotherapy market is expected to reach USD 119.39 billion by 2021 from USD 61.97 billion in 2016, at a CAGR of 14.0% from 2016 to 2021. Factors such as increasing incidence of cancer, rising healthcare expenditure, and increased access to medical insurance in developed countries are driving growth in the caner immunotherapy market. However, stringent regulatory policies and side-effects associated with cancer therapy are the major factors restraining the growth of this market.

The global cancer immunotherapy market has been segmented on the basis of type, application, end user, and region. The monoclonal antibodies segment is expected to register the highest growth rate in the cancer immunotherapy market, by type, during the forecast period. Factors such as high success rate and less recovery time are contributing to the high growth in this segment.

Based on application, the global cancer immunotherapy market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and others (renal cell carcinoma, cervical, gastric, and lymphoma). The lung cancer segment is expected to witness the highest CAGR from 2016 to 2021, primarily due to the rising prevalence of this type of cancer.

Based on end users, the global cancer immunotherapy market is segmented into hospitals and clinics & others. The hospitals segment is expected to account for the largest share of the global cancer immunotherapy market in 2016. The rise in healthcare spending has resulted in the increasing use of drugs in hospitals.

Geographically, the cancer immunotherapy market is dominated by North America, followed by Europe, Asia-Pacific, and the Rest of the World (RoW). The large share of North America can be attributed to the growing aging population and the increased funding from government and non-government agencies in order to increase the research capacity.

Apart from comprehensive geographic & product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles comprise the product portfolios, developments, and strategies adopted by the market players to maintain and increase their shares in the market. The above-mentioned market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output, in order to remain successful in the cancer immunotherapy market.

The major players in the cancer immunotherapy market include Amgen (U.S.), AstraZeneca (U.K.), F. Hoffman La-Roche Ltd. (Switzerland), Bayer AG (Germany), Bristol-Myers Squibb (U.S.), Eli Lilly and Company (U.S.), Janssen Global Services, LLC (Belgium), Merck (U.S.), Novartis (Switzerland), and Pfizer (U.S.).

OBJECTIVES OF THE STUDY

• To define, describe, and forecast the global cancer immunotherapy market on the basis of type, application, end user, and region
• To provide detailed information regarding the major factors (drivers, restraints, opportunities, and industry-specific challenges) influencing the growth of the global cancer immunotherapy market
• To strategically analyze the markets with respect to their individual growth trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
• To forecast the revenue of market segments with respect to four regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
• To profile the key players and comprehensively analyze their market shares and core competencies
• To analyze competitive developments such as new product launches; agreements, partnerships, and joint ventures; mergers & acquisitions; and R&D activities in the global cancer immunotherapy market

Target Audience for this Report:

• Drug Manufacturers and Suppliers
• Academic Research Institutes
• Hospitals and Clinics
• Research and Development (R&D) Companies
• Business Research and Consulting Service Providers
• Medical Research Laboratories
• Academic Medical Centers and Universities

Scope of the Report:

In this report, the cancer immunotherapy market has been segmented into the following segments and subsegments:

Cancer Immunotherapy Market, by Type

• Monoclonal Antibodies
• Cancer Vaccines
• Checkpoint Inhibitors
• Immunomodulators

Cancer Immunotherapy Market, by Application

• Lung Cancer
• Breast Cancer
• Head and Neck Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma
• Others

Cancer Immunotherapy Market, by End User

• Hospitals
• Clinics & Others

Cancer Immunotherapy Market, by Region

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• Italy
• U.K.
• Spain
• RoE
• APAC
• India
• China
• Japan
• RoAPAC
• Rest of the World (RoW)
• South America, Central America, and the Caribbean
• Oceania
• Africa

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKETS COVERED
  1.3.1 PERIODIZATION
1.4 CURRENCY
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
  2.1.1 KEY DATA FROM SECONDARY SOURCES
  2.1.2 KEY DATA FROM PRIMARY SOURCES
2.2 MARKET SIZE ESTIMATION
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 MARKET SHARE ESTIMATION
2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

3.1 INTRODUCTION
3.2 CURRENT SCENARIO
3.3 FUTURE OUTLOOK
  3.3.1 FUTURE OF CANCER IMMUNOTHERAPEUTICS

4 PREMIUM INSIGHTS

4.1 LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 DRIVERS
  5.2.1 RISE IN INCIDENCE OF CANCER
  5.2.2 INCREASE IN ADOPTION OF IMMUNOTHERAPY OVER OTHER TREATMENT OPTIONS
  5.2.3 DEVELOPMENT OF BIOINFORMATIC TOOLS ENHANCING DRUG DEVELOPMENT PROCESS
5.3 RESTRAINTS
  5.3.1 HIGH COST OF TREATMENT
5.4 OPPORTUNITIES
  5.4.1 INCREASE IN CLINICAL TRIALS AGAINST SEVERAL TYPES OF CANCERS IN IMMUNOTHERAPY
  5.4.2 HIGH GROWTH PROSPECTS IN DEVELOPING COUNTRIES
5.5 CHALLENGES
  5.5.1 AVAILABILITY OF LIMITED FUNDS TO INITIATE CLINICAL TRIALS
  5.5.2 COMPLEXITY OF CANCER LIMITING THE IMMUNE RESPONSE
5.6 OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING
5.7 CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY

6 INDUSTRY TRENDS

6.1 GLOBAL TRENDS IN THE CANCER IMMUNOTHERAPY MARKET
  6.1.1 FDA APPROVALS FOR OPDIVO (NIOLUMAB) AND KEYTRUDA (PEMBROLIZUMAB) IN THE U.S. PRESENT ATTRACTIVE OPPORTUNITIES
  6.1.2 COMBINATION IMMUNOTHERAPY A POTENTIAL WAY TO TREAT MELANOMA
  6.1.3 U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020
  6.1.4 U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES
  6.1.5 WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY
  6.1.6 A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE THE SURVIVAL RATE OF PATIENTS IN CHINA
6.2 PRICING VARIATIONS IN THE GLOBAL CANCER IMMUNOTHERAPY MARKET
6.3 SMALL PLAYERS COLLABORATING TO MAKE LONG-TERM IMPACT IN THE CANCER IMMUNOTHERAPY MARKET
6.4 ATTRACTIONS FOR THE PHARMACEUTICAL INDUSTRY
6.5 HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS
  6.5.1 BREAST CANCER
  6.5.2 LUNG CANCER
  6.5.3 MULTIPLE MYELOMA
  6.5.4 LYMPHOMA

7 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE

7.1 INTRODUCTION
7.2 MONOCLONAL ANTIBODIES
  7.2.1 NAKED MONOCLONAL ANTIBODIES
  7.2.2 CONJUGATED MONOCLONAL ANTIBODIES
  7.2.3 BISPECIFIC MONOCLONAL ANTIBODIES
7.3 VACCINES
  7.3.1 PROPHYLACTIC VACCINES
  7.3.2 THERAPEUTIC VACCINES
7.4 CHECKPOINT INHIBITORS
  7.4.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)
  7.4.2 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)
7.5 CELL THERAPIES
  7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
  7.5.2 DENDRITIC CELLS
7.6 IMMUNOMODULATORS
  7.6.1 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF & G-CSF)
  7.6.2 INTERFERONS (IFN)
  7.6.3 INTERLEUKINS (IL)
  7.6.4 ONCOLYTIC VIRUS
    7.6.4.1 Immunotherapy
    7.6.4.2 Immunity as an obstacle
    7.6.4.3 Immunity as an ally
    7.6.4.4 Approved Products & Clinical Trails

8 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

8.1 INTRODUCTION
8.2 LUNG CANCER
8.3 BREAST CANCER
8.4 MULTIPLE MYELOMA
8.5 COLORECTAL CANCER
8.6 HEAD & NECK CANCER
8.7 PROSTATE CANCER
8.8 MELANOMA
8.9 OTHER CANCER TYPES

9 CANCER IMMUNOTHERAPY MARKET, BY END USER

9.1 INTRODUCTION
9.2 HOSPITALS
9.3 CLINICS & OTHERS

10 CANCER IMMUNOTHERAPY MARKET, BY REGION

10.1 INTRODUCTION
10.2 NORTH AMERICA
10.3 EUROPE
10.4 ASIA-PACIFIC
10.5 REST OF THE WORLD (ROW)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 MARKET SHARE ANALYSIS
11.3 COMPETITIVE SITUATION AND TRENDS
  11.3.1 APPROVALS
  11.3.2 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS
  11.3.3 ACQUISITIONS
  11.3.4 EXPANSIONS
  11.3.5 OTHER DEVELOPMENTS

12 COMPANY PROFILE

(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*

12.1 AMGEN INC.
12.2 ASTRAZENECA
12.3 BAYER AG
12.4 BRISTOL-MYERS SQUIBB
12.5 ELI LILLY AND COMPANY
12.6 JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON)
12.7 MERCK
12.8 NOVARTIS
12.9 PFIZER
12.10 F. HOFFMANN-LA ROCHE LTD 130.

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 INSIGHTS FROM INDUSTRY EXPERTS
13.2 DISCUSSION GUIDE
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
13.5 AVAILABLE CUSTOMIZATIONS
13.6 RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1 OVERVIEW OF FUNDING PATTERNS FOR DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012–2017 (USD MILLION)
Table 2 OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016
Table 3 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 4 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)
Table 5 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 6 NAKED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 7 CONJUGATED MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 8 BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 9 VACCINES MARKET SIZE, BY SUBTYPE, 2016–2021 (USD MILLION)
Table 10 VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 11 PROPHYLACTIC VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 12 THERAPEUTIC VACCINES MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 13 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)
Table 14 CHECKPOINT INHIBITORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 15 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 16 PD-1 & PD-L1 MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 17 IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION)
Table 18 IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 19 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 20 INTERFERONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 21 INTERLEUKINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 22 CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION)
Table 23 LUNG CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 24 BREAST CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 25 MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 26 COLORECTAL CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 27 HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 28 PROSTATE CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 29 MELANOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 30 OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 31 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2014–2021 (USD MILLION)
Table 32 HOSPITALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 33 CLINICS & OTHERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 34 CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION)
Table 35 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2016–2021(USD MILLION)
Table 36 EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 37 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 38 ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION)
Table 39 APPROVALS, 2013–2016
Table 40 AGREEMENTS, PARTNERSHIPS & COLLABORATIONS, 2013–2016
Table 41 ACQUISITIONS, 2013–2016
Table 42 EXPANSIONS, 2013–2016

List Of Figures

LIST OF FIGURES

Figure 1 CLASSIFICATION OF CANCER IMMUNOTHERAPY
Figure 2 RESEARCH DESIGN
Figure 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
Figure 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
Figure 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION
Figure 6 DATA TRIANGULATION METHODOLOGY
Figure 7 THE MONOCLONAL ANTIBODY SEGMENT IS EXPECTED TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET DURING THE FORECAST PERIOD
Figure 8 THE LUNG CANCER SEGMENT LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015
Figure 9 HOSPITALS ARE MAJOR END USERS OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET
Figure 10 NORTH AMERICA LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015
Figure 11 GLOBAL CANCER IMMUNOTHERAPY MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD
Figure 12 LUNG CANCER APPLICATION DOMINATED THE GLOBAL CANCER IMMUNOTHERAPY MARKET, 2016
Figure 13 ROW TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD
Figure 14 LUNG CANCER TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD IN THE CANCER IMMUNOTHERAPY MARKET
Figure 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
Figure 16 PROJECTED INCREASE IN CANCER CASES, EXCLUDING NON-MELANOMA SKIN CANCER, 2012 VS. 2020
Figure 17 PRICING TREND OF IMBRUVICA ACROSS THE MAJOR PHARMACEUTICAL MARKET IN 2016
Figure 18 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR BREAST CANCER
Figure 19 ANNUAL COST OF BREAST CANCER IMMUNOTHERAPY, 2016
Figure 20 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LUNG CANCER
Figure 21 ANNUAL COST OF LUNG CANCER IMMUNOTHERAPY, 2016
Figure 22 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR MULTIPLE MYELOMA
Figure 23 ANNUAL COST OF MULTIPLE MYELOMA IMMUNOTHERAPY, 2016
Figure 24 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LYMPHOMA
Figure 25 ANNUAL COST OF LYMPHOMA IMMUNOTHERAPY, 2016
Figure 26 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE
Figure 27 MONOCLONAL ANTIBODIES SEGMENT IS ESTIMATED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN 2016
Figure 28 NAKED MONOCLONAL ANTIBODIES ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE IN 2016
Figure 29 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER MONOCLONAL ANTIBODIES MARKET IN 2016
Figure 30 VACCINES MARKET, BY SUBTYPE, 2016–2021 (USD MILLION)
Figure 31 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING IN THE VACCINES MARKET
Figure 32 PROGRAMMED DEATH 1(PD-1) IS PROJECTED TO BE THE FASTER-GROWING SEGMENT OF THE CHECKPOINT INHIBITORS MARKET
Figure 33 ROW IS PROJECTED TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE CHECKPOINT INHIBITORS MARKET
Figure 34 GM-CSF & G-CSF SUB-SEGMENT IS PROJECTED TO DOMINATE THE IMMUNOMODULATORS SEGMENT THROUGH 2021
Figure 35 NORTH AMERICA IS PROJECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE IMMUNOMODULATORS MARKET THROUGH 2021
Figure 36 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION
Figure 37 LUNG CANCER SEGMENT IS ESTIMATED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN 2016
Figure 38 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE LUNG CANCER IMMUNOTHERAPY MARKET IN 2016
Figure 39 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER IN 2016
Figure 40 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR MULTIPLE MYELOMA IN 2016
Figure 41 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER IN 2016
Figure 42 NORTH AMERICA IS ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER IN 2016
Figure 43 NORTH AMERICA IS ESTIMATED TO DOMINATE THE IMMUNOTHERAPY MARKET FOR PROSTATE CANCER IN 2016
Figure 44 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE CANCER IMMUNOTHERAPY MARKET FOR MELANOMA DURING THE FORECAST PERIOD
Figure 45 ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE IMMUNOTHERAPY MARKET FOR OTHER CANCER TYPES, 2016-2021
Figure 46 CANCER IMMUNOTHERAPY MARKET, BY END USER, 2016 VS. 2021 (USD MILLION)
Figure 47 HOSPITALS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
Figure 48 CLINICS & OTHERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION)
Figure 49 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION FROM 2016 TO 2021
Figure 50 ROW REGION IS PROJECTED TO GROW AT THE HIGHEST RATE FROM 2016 TO 2021
Figure 51 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016
Figure 52 THE CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO BE THE FASTEST-GROWING THROUGH 2021
Figure 53 MONOCLONAL ANTIBODIES SEGMENT IS PROJECTED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN EUROPE THROUGH 2021
Figure 54 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016
Figure 55 CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN THE ROW REGION THROUGH 2021
Figure 56 COMPANIES ADOPTED APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS
Figure 57 GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2015
Figure 58 APPROVALS: THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015
Figure 59 AMGEN INC.: COMPANY SNAPSHOT
Figure 60 ASTRAZENECA: COMPANY SNAPSHOT
Figure 61 BAYER AG: COMPANY SNAPSHOT
Figure 62 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT
Figure 63 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
Figure 64 JANSSEN GLOBAL SERVICES, LLC: COMPANY SNAPSHOT
Figure 65 MERCK: COMPANY SNAPSHOT
Figure 66 NOVARTIS: COMPANY SNAPSHOT
Figure 67 PFIZER: COMPANY SNAPSHOT
Figure 68 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT